Clinical trial
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic…
NCT00063934 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00063934 |
|---|---|
| Title | Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer |
| Official title | A Phase 1/2 Study of Bcl-2 Antisense Oligonucleotide G3139 in Combination With Doxorubicin and Docetaxel in Metastatic and Locally Advanced Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Drug, Other, Procedure |
| Interventions | oblimersen sodium, doxorubicin hydrochloride, docetaxel, filgrastim, pegfilgrastim, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis |
| Enrollment | 31 |
| Start date | May 1, 2003 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Jul 9, 2003 |
| Last update posted | Mar 5, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: